Company

Company

We improve the health and well-being of patients around the world.

Four business divisions united by a shared commitment to quality, safety and on-going innovation.

Commitment

Commitment

Patients inspire the work we do every day.

We support the development of the scientific community and its research efforts.

Innovation

Innovation

Take a look at the portfolio of products and therapies currently in development.

AMBAR, an ambitious research project on Alzheimer's.

AMBAR

AMBAR

Take a look at the information about the AMBAR study

The AMBAR trial results

Team

Team

We strive to cultivate a friendly, diverse and inclusive work environment.

Grifols is becoming increasingly global. A diverse team will remain a key component to our future success.

Products and services

MEDIA

Latest news

05 nov, 2018 Bioscience Division revenues drive operational growth to 9.6% in the third quarter and boost net profits to Euros 468 million
Read more

27 oct, 2018 Grifols AMBAR results demonstrate a significant reduction in the progression of moderate Alzheimer's Disease
Read more

22 oct, 2018 Grifols invests in ultrahigh sensitive disease diagnostic and prognostic technology
Read more

Media contacts

Journalist or media professional?

Our Media Relations team is available at:
(+34) 93 571 00 02
media@grifols.com.
Restricted to media inquiries only.

Not a journalist?

For general questions and requests, please contact corporatecomms@grifols.com.

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.

Discover our new corporate site

Latest news

Media contacts